AUPH


Aurinia’s Kidney Disease Treatment Wins FDA Approval; Street Sees 78% Upside

Aurinia Pharmaceuticals announced that the US Food and Drug Administration (FDA) has approved its Lupkynis (voclosporin) treatment for use in adult patients with …

Aurinia Tanks 10% As Dry Eye Trial Fails To Reach Primary Endpoint

Shares in Aurinia Pharmaceuticals (AUPH) tanked 10% after-hours after the biopharma announced disappointing topline data from the Phase 2/3 Audrey clinical study evaluating …

Aurinia Pharma Surges 9% On Priority Review For Lupus Kidney Treatment

Shares in Aurinia Pharma (AUPH) surged 9% in Tuesday’s extended trading after the U.S.

Aurinia Submits FDA New Drug Admission For Novel Voclosporin Kidney Treatment

Shares in Aurinia Pharmaceuticals, Inc (AUPH) advanced in pre-market trading as the biotech company announced the submission of the New Drug Application (NDA) …

3 “Strong Buy” Small-Cap Stocks with Towering Growth Prospects

Finding a stock which will deliver enormous returns is the Street’s holy grail. Upon first glance, this task may seem rather simple.

3 Biotech Stocks That Could Triple in 2020

2019 has not been a great year to own biotech stocks (so far). Since the year began, the Nasdaq Biotechnology Index (NBI) is …

Here’s Why Aurinia Pharmaceuticals (AUPH) Stock Plummeted Today

Aurinia (AUPH) investors got cold feet today, sending shares tumbling nearly 9%. The reason?

Aurinia Pharmaceuticals (AUPH): Takeaways from Cantor Healthcare Conference Presentation

This morning, Aurinia (AUPH) presented at the Cantor 4th Annual Healthcare Conference in New York City, and provided a corporate overview of its clinical …

Cantor Comments on Aurinia Pharmaceuticals (AUPH) Following 1Q18 Update

Cantor analyst Elemer Piros is out with a short research note on shares of Aurinia Pharmaceuticals (NASDAQ:AUPH), following the company’s first-quarter financial results and update on …

Aurinia Pharmaceuticals Inc (AUPH) Is an Attractive Opportunity with 75% Upside

Aurinia potentially has the 1st treatment for lupus nephritis, says RBC Capital’s Douglas Miehm.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts